This (John Hopkins University) report troubles prodrug targeting based on the NAALADase activity of Prostate- Specific Membrane Antigen (PSMA) through prostate cancer.

This (John Hopkins University) report troubles prodrug targeting based on the NAALADase activity of Prostate- Specific Membrane Antigen (PSMA) through prostate cancer. Approximately forty thousand men will die in the U this year from prostate cancer. Although androgen- independent prostatic cancer lonely dwellings are lethal, usually less than 5% are proliferating by day. Since the majority of current chemotherapeutic agents only kill small cavitys effectively when they are proliferating, this may explain for what cause [i]or[/i] reason these agents have been of in the same state [i]or[/i] condition limited success in patients. In contrast to these ineffective agents, a plant toxin, Thapsigargin (TO), has been chemically modified to show primary amine-containing analogs that are influential cell-proliferation-independent inducers of apoptosis in pro-state cancer cells

These TO-analogs, however, are not prostate cancer-specific cytotoxins. Therefore, they must be changeed to inactive prodrugs that can be efficiently renewed back to active killing unsalable articles only by the enzymatic activity of Prostate-Specific Membrane Antigen (PSMA). Since PSMA is exhibited in high levels only from prostate cancer cells and not through normal cells, this should allow specific targeting of the TO-analog's killing ability to prostate cancer enclosed spaces Therefore, prodrugs will be produc through chemical linkage to PSMA-specific peptides, and they will be proofed for their potency and selectivity as PSMA activated killing agents against androgen-independent human prostate cancer small rooms to identify the best candidates for clinical trials.

(Order this LIFE SCIENCES & BIOTECHNOLOGY UPDATE reviewed report from InfoTeam Inc., PO case 15640, Plantation, FL 33318-5640; Phone (954) 473-9560 Fax (954) 473-0544: Report No. L20010822; 1999 12 pp Price: $8900 prepaid.)

...

Home